Rigel Pharmaceuticals (RIGL) Non-Current Assets (2010 - 2026)

Rigel Pharmaceuticals has reported Non-Current Assets for 17 years, with the latest figure at $270.6 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Assets rose 820.06% year-over-year to $270.6 million; the trailing twelve-month figure through Mar 2026 stood at $603.0 million (up 382.68% YoY), and the FY2025 full-year result was $273.4 million, up 847.0% from the prior year.
• Non-Current Assets for Q1 2026 stood at $270.6 million, down from $273.4 million in the prior quarter.
• The five-year high for Non-Current Assets was $273.4 million in Q4 2025, with the low at $5.2 million in Q3 2022.
• Average Non-Current Assets over 5 years is $51.4 million, with a median of $27.6 million recorded in 2025.
• Year-over-year, Non-Current Assets tumbled 66.47% in 2022 and jumped 847.0% in 2025.
• Tracing RIGL's Non-Current Assets over 5 years: stood at $18.4 million in 2022, then fell by 2.27% to $18.0 million in 2023, then soared by 60.77% to $28.9 million in 2024, then jumped by 847.0% to $273.4 million in 2025, then declined by 1.04% to $270.6 million in 2026.
• The last three Non-Current Assets figures came in at $270.6 million (Q1 2026), $273.4 million (Q4 2025), and $27.6 million (Q3 2025), per Business Quant data.

Peer Comparison